CONTESSA

Hospital Care at Home: Henry Ford Health System and Contessa Partner to Create New Choice for Patients

Retrieved on: 
Thursday, September 30, 2021
Other Consumer, Mental Health, Nursing, Women, Seniors, Hospitals, Men, General Health, Consumer, Health, Academic health science centre, Social support, Henry Ford Hospital, Nursing, Partnership, Elective surgery, Henry Ford Health System, Sports medicine, Failure, Palliative care, Pharmacist, Health, SNF, III, NASDAQ, Private Securities Litigation Reform Act, Patient, Multimedia, Patient satisfaction, MI, Cancer, Pharmacy, Physician, Hospital, Home, CEO, Contessa, Company, Rehabilitation, Program, COVID-19, Ford Motor Company, Terrorism, Research, Information, Radiology, Hospice, NIH, Lists of disasters, District, Conditional sentence, Government, Education, Medicine, Risk management, Henry Ford Health System, Contessa, HENRY FORD HEALTH SYSTEM, CONTESSA

Henry Ford Health System announced a new partnership today with the nations leading operator of high-acuity home care, Contessa , an Amedisys company (NASDAQ: AMED).

Key Points: 
  • Henry Ford Health System announced a new partnership today with the nations leading operator of high-acuity home care, Contessa , an Amedisys company (NASDAQ: AMED).
  • Henry Ford Health System is committed to putting its patients at the center of its care delivery, and Henry Ford Hospital Care at Home is a natural extension of that passion.
  • Contessa is honored to partner with Henry Ford to bring this level of care to the people of Michigan, said Contessa CEO Travis Messina.
  • More than 2,500 physicians are also affiliated with the health system through the Henry Ford Physician Network and Jackson Health Network.

Odonate Therapeutics Announces Financial Results for the Three and Twelve Months Ended December 31, 2020

Retrieved on: 
Tuesday, February 23, 2021
Pharmaceutical, Health, Oncology, Clinical trials, Companies, Tesetaxel, CONTESSA, Odonate Therapeutics, Inc.

Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced financial results for the three and twelve months ended December 31, 2020.

Key Points: 
  • Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced financial results for the three and twelve months ended December 31, 2020.
  • As of December 31, 2020, Odonate had $157.3 million in cash, compared to $180.5 million as of December 31, 2019.
  • Positive results of CONTESSA were presented at the 2020 San Antonio Breast Cancer Symposium in December.
  • Odonate Therapeutics, Inc. is a pharmaceutical company dedicated to the development of bestinclass therapeutics that improve and extend the lives of patients with cancer.

Positive Results of CONTESSA, a Phase 3 Study of Tesetaxel in Patients with Metastatic Breast Cancer, Presented at the 2020 San Antonio Breast Cancer Symposium (SABCS)

Retrieved on: 
Friday, December 11, 2020
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Breast cancer, Metastatic breast cancer, Cancer treatments, Cancer, Clinical medicine, Trastuzumab emtansine, Apatinib, Tesetaxel, CONTESSA, Odonate Therapeutics, Inc.

CONTESSA is a multinational, multicenter, randomized, Phase 3 study of tesetaxel, an investigational, orally administered taxane, in patients with MBC.

Key Points: 
  • CONTESSA is a multinational, multicenter, randomized, Phase 3 study of tesetaxel, an investigational, orally administered taxane, in patients with MBC.
  • In patients with metastatic breast cancer, tesetaxel was shown to have significant, single-agent antitumor activity in two multicenter, Phase 2 studies.
  • Tesetaxel currently is the subject of three studies in breast cancer, including a multinational, multicenter, randomized, Phase 3 study in patients with metastatic breast cancer, known as CONTESSA.
  • Positive results of CONTESSA were recently presented at the 2020 San Antonio Breast Cancer Symposium.

Odonate Therapeutics to Host Virtual Investor and Analyst Event on December 11, 2020

Retrieved on: 
Tuesday, December 1, 2020
Oncology, Health, Other Health, General Health, Clinical trials, Pharmaceutical, Biotechnology, Tesetaxel, CONTESSA, Odonate Therapeutics, Inc.

Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced that it will host a virtual Investor and Analyst Event on Friday, December 11, 2020, at 1:00 p.m. CT / 2:00 p.m.

Key Points: 
  • Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced that it will host a virtual Investor and Analyst Event on Friday, December 11, 2020, at 1:00 p.m. CT / 2:00 p.m.
  • In patients with metastatic breast cancer, tesetaxel was shown to have significant, single-agent antitumor activity in two multicenter, Phase 2 studies.
  • Odonate recently announced positive top-line results from CONTESSA, and full results are scheduled to be presented at the San Antonio Breast Cancer Symposium in December 2020.
  • Odonate Therapeutics, Inc. is a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer.

Odonate Therapeutics Announces Financial Results for the Three and Nine Months Ended September 30, 2020

Retrieved on: 
Wednesday, October 28, 2020
Biotechnology, Pharmaceutical, Health, Oncology, Life sciences, Pharmaceutical companies, Companies, Tesetaxel, CONTESSA, CONTESSA 2, CONTESSA TRIO, Odonate Therapeutics, Inc.

Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced financial results for the three and nine months ended September 30, 2020.

Key Points: 
  • Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced financial results for the three and nine months ended September 30, 2020.
  • As of September 30, 2020, Odonate had $188.3 million in cash, compared to $180.5 million as of December 31, 2019.
  • These results have been selected for an oral presentation at the 2020 San Antonio Breast Cancer Symposium in December.
  • Odonate Therapeutics, Inc. is a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer.

Results of CONTESSA, a Phase 3 Study of Tesetaxel in the Treatment of Patients with Metastatic Breast Cancer, to Be Presented at the 2020 San Antonio Breast Cancer Symposium (SABCS)

Retrieved on: 
Monday, October 5, 2020
Oncology, Health, Other Health, General Health, Clinical trials, Pharmaceutical, Biotechnology, Clinical medicine, Cancer, Medicine, Cancer treatments, Antineoplastic drugs, Metastatic breast cancer, Breast cancer, Chemotherapy, Apatinib, Trastuzumab emtansine, Tesetaxel, CONTESSA, Odonate Therapeutics, Inc.

In patients with metastatic breast cancer, tesetaxel was shown to have significant, single-agent antitumor activity in two multicenter, Phase 2 studies.

Key Points: 
  • In patients with metastatic breast cancer, tesetaxel was shown to have significant, single-agent antitumor activity in two multicenter, Phase 2 studies.
  • Tesetaxel currently is the subject of three studies in breast cancer, including a multinational, multicenter, randomized, Phase 3 study in patients with metastatic breast cancer, known as CONTESSA.
  • CONTESSA is a multinational, multicenter, randomized, Phase 3 study of tesetaxel, an investigational, orally administered taxane, in patients with metastatic breast cancer (MBC).
  • Odonates goal for tesetaxel is to develop an effective chemotherapy choice for patients that provides quality-of-life advantages over current alternatives.

Odonate Therapeutics Announces Positive Top-line Results from CONTESSA, a Phase 3 Study of Tesetaxel in Patients with Metastatic Breast Cancer

Retrieved on: 
Monday, August 24, 2020
Oncology, Health, Other Health, General Health, Clinical trials, Pharmaceutical, Biotechnology, Cancer treatments, Cancer, Metastatic breast cancer, Clinical medicine, Breast cancer, Chloroarenes, Trastuzumab emtansine, Genta, Tesetaxel, CONTESSA, Odonate Therapeutics, Inc.

CONTESSA is a multinational, multicenter, randomized, Phase 3 study of tesetaxel, an investigational, orally administered taxane, in patients with MBC.

Key Points: 
  • CONTESSA is a multinational, multicenter, randomized, Phase 3 study of tesetaxel, an investigational, orally administered taxane, in patients with MBC.
  • In patients with metastatic breast cancer, tesetaxel was shown to have significant, single-agent antitumor activity in two multicenter, Phase 2 studies.
  • Tesetaxel currently is the subject of three studies in breast cancer, including a multinational, multicenter, randomized, Phase 3 study in patients with metastatic breast cancer, known as CONTESSA.
  • CONTESSA is a multinational, multicenter, randomized, Phase 3 study of tesetaxel, an investigational, orally administered taxane, in patients with metastatic breast cancer (MBC).

Odonate Therapeutics Announces Financial Results for the Three and Six Months Ended June 30, 2020

Retrieved on: 
Thursday, July 30, 2020
Oncology, Communications, Health, General Health, Pharmaceutical, Public relations, Investor relations, Companies, Life sciences, Industries, Tesetaxel, CONTESSA, CONTESSA 2, CONTESSA TRIO, Odonate Therapeutics, Inc.

Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced financial results for the three and six months ended June 30, 2020.

Key Points: 
  • Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced financial results for the three and six months ended June 30, 2020.
  • As of June 30, 2020, Odonate had $125.4 million in cash, compared to $180.5 million as of December 31, 2019.
  • Net cash used in operating activities for the six months ended June 30, 2020 was $56.5 million, compared to $50.3 million for the same period in 2019.
  • Odonate Therapeutics, Inc. is a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer.

Odonate Therapeutics Announces Financial Results for the Three Months Ended March 31, 2020

Retrieved on: 
Tuesday, April 28, 2020
Oncology, Health, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Companies, Tesetaxel, CONTESSA, CONTESSA 2, CONTESSA TRIO, Odonate Therapeutics, Inc.

Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced financial results for the three months ended March 31, 2020.

Key Points: 
  • Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced financial results for the three months ended March 31, 2020.
  • As of March 31, 2020, Odonate had $153.1 million in cash, compared to $180.5 million as of December 31, 2019.
  • Net cash used in operating activities for the three months ended March 31, 2020 was $27.8 million, compared to $27.1 million for the same period in 2019.
  • Odonate Therapeutics, Inc. is a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer.

Odonate Therapeutics Announces Financial Results for the Three and Twelve Months Ended December 31, 2019

Retrieved on: 
Thursday, February 20, 2020
Oncology, Health, Other Health, General Health, Clinical trials, Pharmaceutical, Biotechnology, Companies, Tesetaxel, CONTESSA, CONTESSA 2, CONTESSA TRIO, Odonate Therapeutics, Inc.

Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced financial results for the three and twelve months ended December 31, 2019.

Key Points: 
  • Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced financial results for the three and twelve months ended December 31, 2019.
  • As of December 31, 2019, Odonate had $180.5 million in cash, compared to $139.1 million as of December 31, 2018.
  • In patients with metastatic breast cancer, tesetaxel was shown to have significant, single-agent antitumor activity in two multicenter, Phase 2 studies.
  • Odonate Therapeutics, Inc. is a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer.